<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - AMINOGLYCOSIDES</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>AMINOGLYCOSIDES</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well.</p>
            </section>
        
            <section class="generalInformation">
              <p>Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20&#8239;mL/ minute.</p>
            </section>
            <section class="generalInformation">
              <p>Ototoxicity and nephrotoxicity occur commonly in patients with renal failure.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Antibiotic-associated colitis, electrolyte disturbances, hypocalcaemia, hypokalaemia, hypomagnesaemia on prolonged therapy, nausea, peripheral neuropathy, stomatitis, vomiting,
              </p>
              <p>
                <strong>veryRare:</strong> Blood disorders, CNS effects, convulsions, encephalopathy, headache,
              </p>
              <p>
                <strong>notKnown:</strong> Auditory damage, impaired neuromuscular transmission, impaired neuromuscular transmission, irreversible ototoxicity, nephrotoxicity, transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery, vestibular damage,
              </p>
        
        
            <section class="advice">
                <h3>Nephrotoxicity</h3>
              <p>Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related)
          </li>
          <li>
            conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission)
          </li>
          <li>
            if possible, dehydration should be corrected before starting an aminoglycoside
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intramuscular use:</strong>
            whenever possible, parenteral treatment should not exceed 7 days
          </li>
          <li>
              <strong>With intravenous use:</strong>
            whenever possible, parenteral treatment should not exceed 7 days
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Serum concentrations</p>
              <p>Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy.</p><p>Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and <b>must </b>be determined in obesity, if high doses are being given and in cystic fibrosis.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Serum aminoglycoside concentrations <b>must</b> be determined in the elderly.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change.</p><p>For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (&#8216;peak&#8217; concentration) and also just before the next dose (&#8216;trough&#8217; concentration). If the pre-dose (&#8216;trough&#8217;) concentration is high, the interval between doses must be increased. If the post-dose (&#8216;peak&#8217;) concentration is high, the dose must be decreased.</p><p>For once daily dose regimens, consult local guidelines on serum concentration monitoring.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Renal function should be assessed before starting an aminoglycoside and during treatment.</p><p>Auditory and vestibular function should also be monitored during treatment.</p>
            </section>
      </section>











      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of AMINOGLYCOSIDES</h2>

          <ul>
            <li><a href="../drug/PHP3478.html">GENTAMICIN</a></li>
            <li><a href="../drug/PHP3486.html">AMIKACIN</a></li>
            <li><a href="../drug/PHP3492.html">TOBRAMYCIN</a></li>
            <li><a href="../drug/PHP3636.html">STREPTOMYCIN</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
